Ear­ly sur­vival da­ta boost Zio­phar­m's 'con­trolled IL-12' im­munother­a­py for glioblas­toma

An un­con­ven­tion­al pair­ing of a gene ther­a­py and an oral drug that promis­es to at­tack re­cur­rent or pro­gres­sive glioblas­toma with con­trolled re­lease of IL-12 has turned up more promis­ing — if ear­ly — over­all sur­vival da­ta. On top of boost­ing its case as a monother­a­py, the da­ta can al­so bode well for a com­bi­na­tion with Re­gen­eron’s PD-1 in­hibitor, Lib­tayo.

Both the treat­ment and its de­vel­op­er, Zio­pharm On­col­o­gy, have come a long way. The stock price peaked in 2015 but cratered in 2016 fol­low­ing a pa­tient death in a Phase I.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.